{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:13:18Z","timestamp":1770351198403,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ijcard.2019.10.035","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T22:47:50Z","timestamp":1572648470000},"page":"90-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Patients with higher body mass index treated with direct \/ novel oral anticoagulants (DOAC \/ NOAC) for atrial fibrillation experience worse clinical outcomes"],"prefix":"10.1016","volume":"301","author":[{"given":"Marko","family":"Lucijanic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Jurin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hrvoje","family":"Jurin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomo","family":"Lucijanic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Starcevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Skelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Glasnovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Catic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andjela","family":"Jurisic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irzal","family":"Hadzibegovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.10.035_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","article-title":"The epidemiology of obesity: a big picture","volume":"33","author":"Hruby","year":"2015","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.ijcard.2019.10.035_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijcard.2019.10.035_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2019.10.035_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17474086.2018.1517040","article-title":"Anticoagulation at the extremes of body weight: choices and dosing","volume":"11","author":"McCaughan","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.ijcard.2019.10.035_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00392-017-1102-5","article-title":"The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review","volume":"106","author":"De Caterina","year":"2017","journal-title":"Clin. Res. Cardiol. : Off. J. German Cardiac Soc."},{"key":"10.1016\/j.ijcard.2019.10.035_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1055\/s-0038-1675816","article-title":"The non-vitamin K antagonist oral anticoagulants in heart disease: section V-special situations","volume":"119","author":"De Caterina","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2019.10.035_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2019.10.035_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2019.10.035_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2019.10.035_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.11613\/BM.2012.018","article-title":"Analysis of censored data","volume":"22","author":"Lucijanic","year":"2012","journal-title":"Biochem. Med."},{"key":"10.1016\/j.ijcard.2019.10.035_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3325\/cmj.2016.57.77","article-title":"Survival analysis in clinical practice: analyze your own data using an Excel workbook","volume":"57","author":"Lucijanic","year":"2016","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.ijcard.2019.10.035_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"SCHULMAN","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2019.10.035_bib13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.11613\/BM.2017.002","article-title":"Survival analysis, more than meets the eye","volume":"27","author":"Lucijanic","year":"2017","journal-title":"Biochem. Med."},{"key":"10.1016\/j.ijcard.2019.10.035_bib14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.theochem.2009.09.011","article-title":"Molecular structure, lipophilicity, solubility, absorption, and polar surface area of novel anticoagulant agents","volume":"916","author":"Remko","year":"2009","journal-title":"J. Mol. Struct.: THEOCHEM"},{"key":"10.1016\/j.ijcard.2019.10.035_bib15","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial","volume":"9","author":"Liesenfeld","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2019.10.035_bib16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2019.10.035_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.10.035_bib18","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2019.10.035_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2018.03.060","article-title":"Impact of BMI on clinical outcomes of NOAC therapy in daily care - results of the prospective Dresden NOAC Registry (NCT01588119)","volume":"262","author":"Tittl","year":"2018","journal-title":"Int. J. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319342603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319342603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:45:55Z","timestamp":1759092355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527319342603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":19,"alternative-id":["S0167527319342603"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.10.035","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with higher body mass index treated with direct \/ novel oral anticoagulants (DOAC \/ NOAC) for atrial fibrillation experience worse clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}